ARS Pharma Reports Strong Neffy Sales, Nears CVS Caremark Formulary Deal
SPRY sits 20% above its 52-week low of $6.66.
Summary
ARS Pharmaceuticals reported Q1 2026 total revenue of $22.7 million, including $17.5 million in U.S. net product revenue for Neffy, alongside a net loss of $60.6 million. The company announced significant commercial progress for Neffy, with a proposal for CVS Caremark formulary inclusion in the final stages of approval, targeting a July 1 effective date. This follows the company's previously stated focus on commercialization efforts, as noted in its last 10-K. Further expanding market access, Florida added Neffy to its unrestricted Medicaid formulary, bringing the total to nine states, and the sales force was expanded to 148 representatives. The FDA also approved removing age criteria for 1mg Neffy in late March, broadening its eligible patient population. The company maintains a cash position of $201 million, which it believes is sufficient to fund operations through cash-flow break-even. Traders will be watching for the definitive update on the CVS Caremark proposal and continued Neffy adoption.
At the time of this announcement, SPRY was trading at $8.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $788.4M. The 52-week trading range was $6.66 to $18.90. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.